Vermillion Inc. (NASDAQ:VRML) focus on development of diagnostic tests

Boston, MA 06/05/2013 (wallstreetpr) – The share prices of Vermillion Inc. (NASDAQ:VRML) had declined by 12.97 percent to close at $3.01 per share for the end of last trading session on Tuesday. The shares of the company had been trading in the range of $2.79 to $3.50 during the day. The shares of Vermillion Inc. (NASDAQ:VRML) had recorded 52 week low price level of $1.03 per share and 52 week high price level of $4.07 per share.

Vermillion Inc. (NASDAQ:VRML) is involved in providing improved diagnostic tests for physicians so that they could better their test results from patients and thereby design effective treatment plans. The company is primarily engaged in the design, development, marketing and commercialization of diagnostic tests for better outcomes. Vermillion Inc. (NASDAQ:VRML) focuses on developing diagnostic tests which would combine several biomarkers into a single, reportable and readable index score.

The diagnostic tests to be developed by Vermillion Inc. (NASDAQ:VRML) would cover diseases such as diabetics, cancer, cardiology and women’s health with initial focus on ovarian cancer. The company’s principal product candidate, OVA1 provides for the assessment of malignant ovarian tumor in women at the pre surgical stage itself, which had thereby addressed an unmet clinical need.

The shares of Vermillion Inc. (NASDAQ:VRML) had witnessed heavy trading volume with nearly 1.08 million shares being exchanged hands on Tuesday, while the average trading volume of the company is at 406,713 shares per day. The company presently holds 15.20 million shares outstanding in the market with 11 percent institutional ownership.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>